The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S.

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Three out of four adults in the United States live with conditions that can increase the risk of severe illness. 9 Chronic ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

With the greater part of third quarter earnings results in the rearview mirror, investors are looking closely at marquee ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...